Toxicology CPT Code Changes for 2016
|
|
- Lynette Reynolds
- 8 years ago
- Views:
Transcription
1 Beginning January 1, 2016, CMS deleted all 2015 drug testing G codes and will continue to not recognize the AMA CPT codes for drug testing. CMS created three G codes for presumptive testing and four G codes for definitive testing. 1. Delete the following G-codes: a. G0431, G0434 b. HCPCS codes G6030 through G Continue to not recognize the AMA CPT codes For presumptive testing, create three G codes. Only one of the three presumptive G codes may be billed per day. 4. For definitive testing, create four G codes. Only one of the four definitive G codes may be billed per day. Presumptive Drug ing : G0477 Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, immunoassay) capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service. : G0478 Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, immunoassay) read by instrument-assisted direct optical observation (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service. : G0479 Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers (eg, immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when performed, per date of service. Definitive Drug ing : G0480 Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative or quantitative, all sources, includes specimen validity testing, per day, 1-7 drug class(es), including metabolite(s) if performed. : G0481 Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative or quantitative, all sources, includes specimen validity testing, per day, 8-14 drug class(es), including metabolite(s) if performed. : G0482 Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative or quantitative, all sources, includes specimen validity testing, per day, drug class(es), including metabolite(s) if performed.) : G0483 Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative or quantitative, all sources, includes specimen validity testing, per day, 22 or more drug class(es), including metabolite(s) if performed.
2 DOS Name Monoacetylmorphine, GC/MS, (HCPCS: G0480) Monoacetylmorphine, Qualitative, (HCPCS: G0480) 202 Acetaldehyde, Blood (HCPCS: G0480) 201 Acetaminophen (HCPCS: G0480) Acetaminophen Confirmation (HCPCS: G0480) 3198 Acetaminophen Screen (HCPCS: G0479) Acetonitrile Exposure Profile, Blood 80320, (HCPCS: G0480) Acetyl Fentanyl, Qualitative, Blood (HCPCS: G0480) Acetyl Fentanyl, Qualitative, Serum (HCPCS: G0480) Acetyl Fentanyl, Qualitative, (HCPCS: G0480) Alcohol Metabolites with Confirmation, (HCPCS: G0480) Alcohol Metabolites, Quantitative, (HCPCS: G0480) 443 Alcohol, Ethyl, Blood (HCPCS: G0480) 8879 Alcohol, Ethyl, Blood (HCPCS: G0480) Alcohol, Ethyl, Enzymatic (HCPCS: G0480) Alcohol, Ethyl, Qualitative, 2128 Alcohol, Ethyl, Qualitative, with Confirmation, Alcohol, Ethyl, Quantitative, Random (HCPCS: G0480) Alcohol, Ethyl, Quantitative (HCPCS: G0480) Alcohol, Ethyl, Qualitative, without Confirmation, Alfentanil Screen, (HCPCS: G0479) 4741 Alprazolam (Xanax) (HCPCS: G0480)
3 DOS Name Alprazolam and Metabolite Confirmation (HCPCS: G0480) Alprazolam and Metabolite Screen Alprazolam, Quantitative, (HCPCS: G0480) 423 Amitriptyline (HCPCS: G0480) 244 Amobarbital (HCPCS: G0480) Amoxapine and Metabolite (HCPCS: G0480) Amphetamine Confirmation, GC/MS, Blood 80359, (HCPCS: G0480) Amphetamine Confirmation, GC/MS, 80359, (HCPCS: G0480) Amphetamine Confirmation, GC/MS, Serum 80359, (HCPCS: G0480) Amphetamine Screen with Confirmation, Blood Amphetamine Screen with Confirmation, Serum Amphetamine Screen, with Confirmation, 6028 Amphetamine, Confirmation, GC/MS, Serum (HCPCS: G0480) Amphetamines (HCPCS: G0480) Amphetamines (1000 ng/ml Screen), without Confirmation, Amphetamines (1000 ng/ml Screen), with Confirmation, Amphetamines (200), Qualitative Confirmation, GC/MS, 80324, (HCPCS: G0480) 3035 Amphetamines (D/L Ratio), Blood (HCPCS: G0480) 3038 Amphetamines (D/L Ratio), Serum/Plasma (HCPCS: G0480) 3053 Amphetamines (D/L Ratio), (HCPCS: G0480) Amphetamines Confirmation, Fluid (HCPCS: G0480) Amphetamines Confirmation, GC/MS, Meconium (HCPCS: G0480)
4 DOS Name 3456 Amphetamines Panel, Blood 80326, (HCPCS: G0480) Amphetamines Panel, Serum/Plasma 80326, (HCPCS: G0480) 7170 Amphetamines Screen with Confirmation, 241 Amphetamines, Quantitative, GC/MS, (HCPCS: G0480) Amphetamines-1000 Clinical Screen, with Confirmation, Antidepressant Panel /Gastric, Qualitative (HCPCS: G0480) Antidepressant Panel, Blood 80337, 80338, (HCPCS: G0480) Antidepressant Panel, 80337, 80338, (HCPCS: G0480) Antidepressants Panel 1, Serum/Plasma 80337, (HCPCS: G0480) Antidepressants Panel, Serum/Plasma 80337, 80338, (HCPCS: G0480) Barbiturate Presumptive Screen Barbiturates Clinical Screen, with Confirmation, Barbiturates Clinical Screen, with Confirmation, Barbiturates Confirmation, Fluids (HCPCS: G0480) Barbiturates Confirmation, Serum/Plasma (HCPCS: G0480) Barbiturates Confirmation, Stool (HCPCS: G0480) Barbiturates Confirmation, (HCPCS: G0480) 3473 Barbiturates Panel, Blood (HCPCS: G0480) Barbiturates Panel, (HCPCS: G0480) 7171 Barbiturates Screen, with Confirmation, 8416 Barbiturates, GC/MS, (HCPCS: G0480) Barbiturates, Qualitative, GC/MS, (HCPCS: G0480)
5 DOS Name 7377 Barbiturates, Quantitative GC/MS Confirmation, Serum (HCPCS: G0480) 8568 Barbiturates, (HCPCS: G0480) Barbiturates, without Confirmation, Bath Salts Panel, Blood (HCPCS: G0480) Bath Salts Panel, Serum/Plasma (HCPCS: G0480) Benzodiazepine, GC/MS, (HCPCS: G0480) Benzodiazepines Clinical Screen, with Confirmation, Benzodiazepines Confirmation Qualitative, Meconium (HCPCS: G0480) Benzodiazepines Confirmation, Serum/Plasma (HCPCS: G0480) Benzodiazepines Panel, Blood (HCPCS: G0480) 7172 Benzodiazepines Screen with Confirmation, Benzodiazepines Screen, Serum/Plasma Benzodiazepines, Confirmation (HCPCS: G0480) Benzodiazepines, HPLC, Serum (HCPCS: G0480) Benzodiazepines, LC/MS/MS, Serum (HCPCS: G0480) Benzodiazepines, Qualitative, GC/MS, (HCPCS: G0480) Benzodiazepines, Quantitative, GC/MS, (HCPCS: G0480) Benzodiazepines, Quantitative, (HCPCS: G0480) 8417 Benzodiazepines, Quantitative, GC/MS, (HCPCS: G0480) Benzodiazepines, without Confirmation, Benzodiazepines, Qualitative, GC/MS, (HCPCS: G0480) Buprenorphine and Metabolite Screen
6 DOS Name Buprenorphine and Metabolite Screen, Blood Buprenorphine and Naloxone, LC/MS/MS 80348, (HCPCS: G0480) Buprenorphine Screen, with Quantitative Confirmation, Buprenorphine, Qualitative, (HCPCS: G0480) Buprenorphine, Qualitative, without Confirmation, Buprenorphine, Quantitative, (HCPCS: G0480) 8592 Bupropion and Metabolite, Serum/Plasma (HCPCS: G0480) 4413 Butalbital (HCPCS: G0480) 6065 Butorphanol Free (Unconjugated), Serum/Plasma (HCPCS: G0480) 8421 Cannabinoids (HCPCS: G0480) Cannabinoids Confirmation, Fluids (HCPCS: G0480) Cannabinoids Confirmation, Meconium (HCPCS: G0480) Cannabinoids Confirmation, Stool (HCPCS: G0480) Cannabinoids Panel Qualitative, Meconium (HCPCS: G0480) Cannabinoids Panel, Serum/Plasma (HCPCS: G0480) 312 Carisoprodol and Metabolite (HCPCS: G0480) Carisoprodol and Metabolite, (HCPCS: G0480) Carisoprodol Screen (HCPCS: G0479) Carisoprodol Screen with Reflex Confirmation (HCPCS: G0479) Chloral Hydrate, Blood Chlordiazepoxide (HCPCS: G0480) Chlordiazepoxide and Metabolites (HCPCS: G0480)
7 DOS Name 882 Chlorpromazine (HCPCS: G0480) Clobazam (HCPCS: G0480) Clomipramine (HCPCS: G0480) Clonazepam and 7-amino Clonazepam, (HCPCS: G0480) Clonazepam and Metabolite, Serum/Plasma (HCPCS: G Clonazepam, serum (HCPCS: G0480) Clorazepate (Tranxene ) (HCPCS: G0480) Cocaine and Metabolite Screen with Confirmation, Meconium Cocaine and Metabolites Confirmation, Qualitative, Meconium (HCPCS: G0480) Cocaine and Metabolites Screen, Blood Cocaine and Metabolites Screen, Serum/Plasma Cocaine and Metabolites, Confirmation, Fluid (HCPCS: G0480) Cocaine Metabolite-100, Qualitative, GC/MS, (HCPCS: G0480) Cocaine Metabolites Clinical Screen, with Confirmation, Cocaine Metabolites Clinical Screen, with Confirmation, Cocaine Metabolites Clinical Screen, without Confirmation, 7173 Cocaine Metabolites Screen with Confirmation, 6092 Cocaine Metabolites, Qualitative, or Gastric 6093 Cocaine Metabolites, Qualitative, GC/MS, (HCPCS: G0480) 5530 Cocaine Metabolites, GC/MS, (HCPCS: G0480) Cocaine, Confirmation, Blood, GC/MS (HCPCS: G0480) Cocaine, Confirmation, GC/MS (HCPCS: G0480)
8 DOS Name Cocaine, Confirmation, GC/MS, Meconium (HCPCS: G0480) 970 ine and Metabolite - Free (Unconjugated), Serum/Plasma (HCPCS: G0480) Comprehensive Drug Screen, Serum 80337, 80324, 80338, 80155, 80156, 80377, 80342, 80332, 80346, 80353, 80361, 80323, 80369, 80354, 80332, 80357, 80362, 80176, 80359, 80358, 80365, 83992, 80190, 80372, (HCPCS: G0483) Confirmed Infant Drug Abuse Screen #3, Meconium CordStat , 80359, 80345, 80346, 80353, 80358, 80362, 80361, 83992, 80365, 80367, 80349, (HCPCS: G0481) CordStat 12 plus EtOH 80324, 80359, 80345, 80346, 80353, 80358, 80362, 80361, 83992, 80365, 80367, 80349, 80373, (HCPCS: G0481) CordStat , 80359, 80345, 80348, 80346, 80353, 80358, 80362, 80361, 83992, 80365, 80367, 80349, (HCPCS: G0481) CordStat 13 plus EtOH CordStat CordStat 5 plus EtOH CordStat CordStat 7 plus EtOH CordStat CordStat 9 plus EtOH 80324, 80359, 80345, 80348, 80346, 80353, 80358, 80362, 80361, 83992, 80365, 80367, 80349, 80373, (HCPCS: G0482) 80324, 80359, 80353, 80361, 83992, (HCPCS: G0480) 80324, 80359, 80353, 80361, 83992, 80349, (HCPCS: G0480) 80324, 80359, 80345, 80353, 80358, 80361, 83992, (HCPCS: G0481) 80324, 80359, 80345, 80353, 80358, 80361, 83992, 80349, (HCPCS: G0481) 80324, 80359, 80345, 80346, 80353, 80358, 80361, 83992, 80367, (HCPCS: G0481) 80324, 80359, 80345, 80346, 80353, 80358, 80361, 83992, 80367, 80349, (HCPCS: G0481)
9 DOS Name Cotinine (HCPCS: G0479) DAP 5-50, Semi-Quantitative with THC Creatinine Ratio without Confirmation 80301, (HCPCS: G0479) 412 Desipramine (HCPCS: G0480) 6103 Dextromethorphan, Qualitative, or Gastric 3245 Dextrorphan/Levorphanol Screen, S/P (HCPCS: G0479) Diazepam and Metabolite (HCPCS: G0480) Diazepam, Quantitative (HCPCS: G0480) Dihydrotestosterone, Free, Serum (HCPCS: G0480) Dihydrotestosterone, LC/MS/MS (HCPCS: G0480) 6109 Dimethadione, Serum/Plasma (HCPCS: G0480) Diuretic Panel (HCPCS: G0480) Diuretics Screen, (HCPCS: G0479) 826 Doxepin (HCPCS: G0480) Drug Abuse Panel Drug Abuse Panel 10 plus Ethanol, without Confirmation Drug Abuse Panel 10 Plus Ethanol Drug Abuse Panel 10 with Confirmation, Drug Abuse Panel 10, without Confirmation, Drug Abuse Panel Plus Ethanol with Confirmation, Drug Abuse Panel with Confirmation, 2179 Drug Abuse Panel plus Ethanol, with Confirmation, Drug Abuse Panel Plus Ethanol, with Confirmation,
10 DOS Name 2125 Drug Abuse Panel plus Ethanol, without Confirmation, Drug Abuse Panel with Methadone 150, EDDP, No Confirmation Drug Abuse Panel with Confirmation, (Refl) 2127 Drug Abuse Panel 10-20, with Confirmation, Drug Abuse Panel 10-20, with Confirmation, 2124 Drug Abuse Panel 10-20, without Confirmation, Drug Abuse Panel (Refl) Drug Abuse Panel (Refl) without Confirmation Drug Abuse Panel Ethanol (Refl) Drug Abuse Panel Plus Ethanol with Confirmation, 2180 Drug Abuse Panel plus Ethanol, with Confirmation, 2130 Drug Abuse Panel plus Ethanol, without Confirmation, Drug Abuse Panel plus Ethanol without Confirmation Drug Abuse Panel with Confirmation, Drug Abuse Panel with Confirmation, Drug Abuse Panel with Confirmation, (Refl) 8254 Drug Abuse Panel without Confirmation, 2126 Drug Abuse Panel 10-50, with Confirmation, Drug Abuse Panel 3-20 with Confirmation, (Refl) Drug Abuse Panel 3-50, without Confirmation, Drug Abuse Panel 4 without Confirmation, Drug Abuse Panel 4 without Confirmation,
11 DOS Name Drug Abuse Panel 4-50 without Confirmation, Drug Abuse Panel 5 without Confirmation, Drug Abuse Panel 5, No Confirmation Drug Abuse Panel 5-100, without Confirmation, Drug Abuse Panel 5-20 with Confirmation, Drug Abuse Panel Drug Abuse Panel Ethanol, No Confirmation Drug Abuse Panel 5-50 Plus Ethanol with Confirmations, Drug Abuse Panel 5-50 with Confirmation, Drug Abuse Panel 5-50 without Confirmation, Drug Abuse Panel 5-50 without Confirmation, Drug Abuse Panel 5-50 without Confirmation, Drug Abuse Panel 5-50 without Confirmation, Drug Abuse Panel 5-50 without Confirmation, Drug Abuse Panel 5-50 Plus Ethanol with Confirmations, Drug Abuse Panel 5-50, No Confirmation Drug Abuse Panel 5-50, with Confirmation, Drug Abuse Panel 5-50, with THC Quantitative Confirmation, Drug Abuse Panel 6 plus Ethanol, with Confirmation, Drug Abuse Panel 6 plus Ethanol, with Confirmation, Drug Abuse Panel 6 plus Ethanol, without Confirmation Drug Abuse Panel 6, without Confirmation,
12 DOS Name Drug Abuse Panel Plus Ethanol without Confirmation, Drug Abuse Panel with Confirmation, Drug Abuse Panel without Confirmation, Drug Abuse Panel 6-100, with Confirmation Drug Abuse Panel 6-100, with Confirmation Drug Abuse Panel 6-100, without Confirmation, Drug Abuse Panel 6-100, without Confirmation, Drug Abuse Panel Drug Abuse Panel Drug Abuse Panel Ethanol Drug Abuse Panel Ethanol Drug Abuse Panel 6-20 Plus Ethanol without Confirmation, 649 Drug Abuse Panel 6-20 Special, with Confirmation, Drug Abuse Panel 6-20 with Confirmation, Drug Abuse Panel 6-20, No Confirmation Drug Abuse Panel Ethanol, No Confirmation Drug Abuse Panel 6-50 Plus Ethanol without Confirmation, Drug Abuse Panel 6-50 Plus Ethanol without Confirmation, Drug Abuse Panel 6-50 plus Ethanol, with Confirmation, Drug Abuse Panel 6-50 Plus Ethanol, Drug Abuse Panel 6-50 with Confirmation, Drug Abuse Panel 6-50 with Confirmation,
13 DOS Name Drug Abuse Panel 6-50 with Confirmation, 8262 Drug Abuse Panel 6-50 without Confirmation, Drug Abuse Panel 6-50 without Confirmation, Drug Abuse Panel 6-50 without Confirmation, Drug Abuse Panel 6-50, with Confirmation, Drug Abuse Panel Drug Abuse Panel Drug Abuse Panel 7 plus Ethanol, Newborn Panel Drug Abuse Panel 7 with Confirmation, Drug Abuse Panel 7, with Confirmation, Drug Abuse Panel 7, without Confirmation Drug Abuse Panel 7-20 with Confirmation, Drug Abuse Panel 7-20 with Confirmation, Drug Abuse Panel Drug Abuse Panel 7-50 plus Ethanol, with Confirmation, Drug Abuse Panel 7-50 with Confirmation, Drug Abuse Panel 7-50 with Confirmation, Drug Abuse Panel 7-50 with Confirmation, Drug Abuse Panel 7-50, No Confirmation Drug Abuse Panel 7-50, No Confirmation Drug Abuse Panel 7-50, without Confirmation, Drug Abuse Panel 8 without Confirmation,
14 DOS Name Drug Abuse Panel 8, with Confirmation, Drug Abuse Panel with Confirmation, Drug Abuse Panel without Confirmation, Drug Abuse Panel 8-100, without Confirmation, Drug Abuse Panel 8-20 with Confirmation, Drug Abuse Panel 8-20 with Confirmation, Drug Abuse Panel 8-20, Drug Abuse Panel 8-50 Plus Ethanol without Confirmation, Drug Abuse Panel 8-50 plus Ethanol, without Confirmation Drug Abuse Panel 8-50 with Confirmation, Drug Abuse Panel 8-50 with Confirmation, Drug Abuse Panel 8-50 without Confirmation, Drug Abuse Panel 8-50, No Confirmation Drug Abuse Panel 8-50, No Confirmation Drug Abuse Panel 8-50, No Confirmation Drug Abuse Panel 8-50, with Confirmation, Drug Abuse Panel 8-50, without Confirmation (REFL) Drug Abuse Panel 9 + Ethanol Drug Abuse Panel 9 + Ethanol Drug Abuse Panel 9 plus Ethanol, with Confirmation Drug Abuse Panel 9, No Confirmation Drug Abuse Panel 9, Serum
15 DOS Name Drug Abuse Panel 9, with Confirmation, Drug Abuse Panel with Confirmation, Drug Abuse Panel 9-100, with Confirmation, Drug Abuse Panel 9-100, with Confirmation, Drug Abuse Panel Drug Abuse Panel Drug Abuse Panel Drug Abuse Panel Ethanol Drug Abuse Panel 9-20 Plus Ethanol with Confirmation, Drug Abuse Panel 9-20 Plus Ethanol without Confirmation, Drug Abuse Panel 9-20, No Confirmation Drug Abuse Panel Drug Abuse Panel Ethanol Drug Abuse Panel Ethanol, No Confirmation Drug Abuse Panel 9-50 Plus Ethanol with Confirmation, Drug Abuse Panel 9-50 Plus Ethanol without Confirmation, Drug Abuse Panel 9-50 with Confirmation, Drug Abuse Panel 9-50 with Confirmation, Drug Abuse Panel 9-50, with Confirmation, Drug Abuse Panel 9-50, with Confirmation, Drug Abuse Panel 9-50, without Confirmation (REFL) Drug Abuse Panel 9-50, without Confirmation,
16 DOS Name 8255 Drug Abuse Panel 9-50, without Confirmation, Drug Abuse Panel 9-50, without Confirmation, Drug Abuse Screen 5 without Confirmation, Serum Drug Abuse Screen 6 with Confirmation Drug Abuse Screen 7 with Confirmation, Serum Drug and Alcohol Screen Drug Panel 10, Quantitative, Drug Panel 10-20, Quantitative Drug Panel Plus Ethanol with Confirmation, Drug Panel 10-50, Quantitative, Drug Panel 10-50, Quantitative, Drug Panel , Quantitative with Confirmation, Drug Panel 6, Quantitative, Drug Panel 8 (no THC), with Confirmation, Drug Screen 1 with Confirmation, Drug Screen 13, No Confirm (HCPCS: G0477) 451 Drug Screen Panel 1, Meconium 463 Drug Screen Panel 2, Meconium 453 Drug Screen Panel 4, Meconium 454 Drug Screen Panel 5, Meconium Drug Screen Panel 9, Meconium 1025 Drug Screen, Clinical 1, without Confirmation, Serum 80329, 80320, (HCPCS: G0479, G0480)
17 DOS Name Drug Screen, Clinical 1, without Confirmation, 5229 Drug Screen, Comprehensive, with Confirmation, Serum 80301, 80329, 80345, (HCPCS: G0479, G0480) Drug Screen, Comprehensive, with Confirmation, Serum,, Gastric 80301, 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, 80377, 80301, 80329, 80345, , 80301, 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, (HCPCS: G0479, G0483) 6635 Drug Screen, Comprehensive, with Confirmation, 80301, 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, (HCPCS: G0479, G0482) 6640 Drug Screen, Comprehensive, with Confirmation,, Serum 80301, 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, 80377, 80301, 80329, 80345, 80369, (HCPCS: G0479. G0482) Drug Screen, Comprehensive, without Confirmation, Gastric 80301, 80337, 80326, 80329, 80338, 80345, 80339, 80370, 80363, 80368, 80332, 80342, 80358, 80323, 80365, 83992, 80320, (HCPCS: G0479, G0482) Drug Screen, Pain 1 with Confirmation, Drug Screen, Serum/Plasma Drug Screen, Serum/Plasma Drug, General Toxicology, Blood 80320, 80346, 80356, 80357, 80330, 80354, 80355, 80366, 80337, 80326, 80323, 80353, 80377, 80345, 80340, 80370, 80344, 80333, 80361, 80364, 80358, 80338, 80360, 80348, 80365, 80367, 83992, 80321, 80372, 80198, 80373, 80368, 80359, (HCPCS: G0483)
18 DOS Name Drug, General Toxicology, Serum 80320, 80346, 80356, 80357, 80330, 80354, 80355, 80366, 80337, 80326, 80323, 80353, 80377, 80345, 80340, 80370, 80344, 80333, 80361, 80364, 80358, 80338, 80360, 80348, 80365, 80367, 83992, 80321, 80372, 80198, 80373, 80368, 80359, (HCPCS: G0483) Drug, General Toxicology, 80320, 80346, 80356, 80357, 80330, 80354, 80355, 80366, 80337, 80326, 80323, 80353, 80377, 80345, 80340, 80370, 80344, 80333, 80361, 80364, 80358, 80338, 80360, 80348, 80365, 80367, 83992, 80321, 80372, 80198, 80373, 80368, 80359, (HCPCS: G0483) Drug Toxicology Amphetamines, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology Barbiturates, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology Benzodiazepines, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology Cocaine, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology Marijuana, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology MDMA, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology Meprobamate, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology Methadone, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology Monitoring 1 Screen, Drug Toxicology Monitoring 1 with Confirmation, Drug Toxicology Monitoring 1, Quantitative, Oral Fluid 80324, 80345, 80346, 80353, 80349, 80359, 80369, 80358, 80323, 80348, 80361, 80354, 80356, 80362, 80365, 80367, 80372, 80373, 83992, (HCPCS: G0482) Drug Toxicology Monitoring 2 Screen, Drug Toxicology Monitoring 2 with Confirmation, Drug Toxicology Monitoring 3 Screen,
19 DOS Name Drug Toxicology Monitoring 3 with Confirmation, Drug Toxicology Monitoring 4 Screen, Drug Toxicology Monitoring 4 with Confirmation, Drug Toxicology Monitoring 5 Screen, Drug Toxicology Monitoring 5 with Confirmation, Drug Toxicology Monitoring 6 Screen, Drug Toxicology Monitoring 6 with Confirmation, Drug Toxicology Monitoring 7 Screen, Drug Toxicology Monitoring 8 Screen, Drug Toxicology Monitoring 8 with Confirmation, Drug Toxicology Monitoring 9 Screen, Drug Toxicology Monitoring 9 with Confirmation, Drug Toxicology Monitoring Alcohol Ethyl, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Alcohol, Ethyl, Screen, Drug Toxicology Monitoring Alcohol, Ethyl, with Confirmation, Drug Toxicology Monitoring Amphetamines, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Amphetamines, Screen, Drug Toxicology Monitoring Barbiturates, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Barbiturates, Screen, Drug Toxicology Monitoring Barbiturates, with Confirmation, Drug Toxicology Monitoring Benzodiazepines, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Benzodiazepines, Screen,
20 DOS Name Drug Toxicology Monitoring Benzodiazepines, with Confirmation, Drug Toxicology Monitoring Buprenorphine, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Buprenorphine, Screen, Drug Toxicology Monitoring Buprenorphine, with Confirmation, Drug Toxicology Monitoring Carisoprodol Metabolite, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Cocaine Metabolite, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Cocaine Metabolite, Screen, Drug Toxicology Monitoring Cocaine Metabolite, with Confirmation, Drug Toxicology Monitoring Fentanyl, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Heroin Metabolite, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Heroin Metabolite, Screen, Drug Toxicology Monitoring Heroin Metabolite, with Confirmation, Drug Toxicology Monitoring Marijuana Metabolite 20, Screen, Drug Toxicology Monitoring Marijuana Metabolite 20, with Confirmation, Drug Toxicology Monitoring Marijuana Metabolite 50, Screen, Drug Toxicology Monitoring Marijuana Metabolite 50, with Confirmation, Drug Toxicology Monitoring Marijuana Metabolite, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring MDMA, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring MDMA, Screen,
21 DOS Name Drug Toxicology Monitoring MDMA, with Confirmation, Drug Toxicology Monitoring Methadone Metabolite, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Methadone Metabolite, Screen, Drug Toxicology Monitoring Methadone Metabolite, with Confirmation, Drug Toxicology Monitoring Opiates Expanded, Quantitative, 80361, (HCPCS: G0480) Drug Toxicology Monitoring Opiates, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Opiates, Screen, Drug Toxicology Monitoring Opiates, with Confirmation, Drug Toxicology Monitoring Oxycodone, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Oxycodone, Screen, Drug Toxicology Monitoring Oxycodone, with Confirmation, Drug Toxicology Monitoring Phencyclidine Screen, Drug Toxicology Monitoring Phencyclidine, with Confirmation, Drug Toxicology Monitoring Propoxyphene, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring Propoxyphene, Screen, Drug Toxicology Monitoring Propoxyphene, with Confirmation, Drug Toxicology Monitoring Tapentadol, Quantitative, (HCPCS: G0480) Drug Toxicology Monitoring 7 with Confirmation, Drug Toxicology Monitoring, Amphetamines, with Confirmation, Drug Toxicology Monitoring, Tramadol, Quantitative, (HCPCS: G0480) Drug Toxicology Nicotine, Quantitative, Oral Fluid (HCPCS: G0480)
22 DOS Name Drug Toxicology Opioids, Quantitative, Oral Fluid 80348, 80354, 80361, 80365, 80367, 80362, 80372, 80373, (HCPCS: G0481) Drug Toxicology PCP, Quantitative, Oral Fluid (HCPCS: G0480) Drug Toxicology Zolpidem, Quantitative, Oral Fluid (HCPCS: G0480) Drugs of Abuse Screen, Serum and Volatiles 3120 Drugs of Abuse Screen (10 Panel), Fluid 722 Ethchlorvynol (Placidyl ) (HCPCS: G0480) 6126 Ethchlorvynol, Qualitative, or Gastric Ethyl Alcohol, Fentanyl and Metabolite, Blood (HCPCS: G0480) Fentanyl and Norfentanyl (HCPCS: G0480) Fentanyl and Norfentanyl, (HCPCS: G0480) Fentanyl Presumptive Screen, (HCPCS: G0479) Fentanyl Screen with Reflex Confirmation Fentanyl, Progressive, 8319 Fioricet 80155, 80345, (HCPCS: G0480, 80155) 8309 Fioricet, Blood 80155, 80345, (HCPCS: G0480, 80155) 8298 Fioricet, 80371, 80345, (HCPCS: G0480) Flunitrazepam and Metabolites Confirmation (HCPCS: G0480) Flunitrazepam and Metabolites Confirmation, (HCPCS: G0480) Flunitrazepam and Metabolites Screen, Flunitrazepam and Metabolites, Quantitative (HCPCS: G0480) Flunitrazepam and Metabolites, Quantitative, (HCPCS: G0480)
23 DOS Name 8389 Fluoxetine (HCPCS: G0480) Fluphenazine, Serum/Plasma (HCPCS: G0480) 422 Glutethimide (HCPCS: G0480) 8827 Gold, Serum/Plasma (HCPCS: G0480) 494 Gold, (HCPCS: G0480) 3135 Halazepam as Metabolite (HCPCS: G0480) Heroin Metabolites, Quantitative, 80361, (HCPCS: G0480) 3154 Heroin Screen, Serum/Plasma Hydrocodone (HCPCS: G0480) Hydrocodone and Metabolite, Serum (HCPCS: G0480) Hydrocodone and Metabolite, (HCPCS: G0480) 8315 Hydrocodone and Metabolites - Free (Unconjugated), Fluid (HCPCS: G0480) 8314 Hydrocodone and Metabolites, Tissue (HCPCS: G0480) Hydromorphone (HCPCS: G0480) 887 Imipramine (HCPCS: G0480) IPECAC USE MARKERS (HCPCS: G0479) Ketamine and Metabolite (HCPCS: G0480) LSD Presumptive Screen (HCPCS: G0479) 6176 LSD Screen (HCPCS: G0479) LSD Screen, Blood (HCPCS: G0480) 8456 LSD Screen, (HCPCS: G0479) LSD Trace Analysis (HCPCS: G0480)
24 DOS Name LSD Trace Analysis, (HCPCS: G0480) Marijuana Confirmation, GC/MS, Meconium (HCPCS: G0480) Marijuana Metabolite, Quantitative, (HCPCS: G0480) Marijuana Metabolite-50 with Creatinine Ratio, without Confirmation Marijuana Metabolites (THC 20 ng/ml) Clinical Screen with Confirmation Marijuana Metabolites (THC 50 ng/ml) Clinical Screen with Confirmation 80301, (HCPCS: G0479) 4846 Marijuana Metabolites, GC/MS, (HCPCS: G0480) Marijuana Metabolites-100 Clinical Screen with Confirmation Marijuana Metabolites-100 Clinical Screen with Confirmation Marijuana Metabolites-100 No Confirmation 7178 Marijuana Metabolites-100 Screen with Confirmation 6317 Marijuana Metabolites-15 by GC/MS, Qualitative, (HCPCS: G0480) Marijuana Metabolites-20 Clinical Screen with Confirmation 2158 Marijuana Metabolites-20 Screen, with Confirmation, Marijuana Metabolites-50 Clinical Screen with Confirmation Marijuana Metabolites-50 No Confirmation 7174 Marijuana Metabolites-50 Screen, with Confirmation, Maternal Substance Abuse Panel 8 Plus MDMA and Metabolite (HCPCS: G0480) MDMA/MDA Screen with Confirmation, MDMA/MDA, Quantitative, (HCPCS: G0480)
25 DOS Name MDPV Stimulant Designer Drug (HCPCS: G0480) MDPV Stimulant Designer Drug, (HCPCS: G0480) 6184 Meclizine Screen (HCPCS: G0479) Meperidine (HCPCS: G0480) Meperidine and Normeperidine, (HCPCS: G0480) Meperidine, GC/MS, (HCPCS: G0480) 6185 Meperidine, Qualitative, Random (HCPCS: G0480) Mephobarbital and Metabolite (HCPCS: G0480) 635 Meprobamate (HCPCS: G0480) 3104 Meprobamate, Quantitative (HCPCS: G0480) Mesoridazine (HCPCS: G0480) 3258 Methadone (HCPCS: G0480) Methadone and Metabolite (100), Qualitative, GC/MS, (HCPCS: G0480) Methadone and Metabolite, (HCPCS: G0480) Methadone by GC/MS, Non Chain of Custody (HCPCS: G0480) Methadone Clinical Screen, with Confirmation, Methadone Clinical Screen, without Confirmation, 7176 Methadone Screen with Confirmation 8418 Methadone, GC/MS, (HCPCS: G0480) 6192 Methadone, Qualitative, GC/MS, (HCPCS: G0480) Methamphetamine and Metabolite, Blood (HCPCS: G0480) Methamphetamine and Metabolite, Quantitative, (HCPCS: G0480)
26 DOS Name Methamphetamine Isomers, D and L (HCPCS: G0480) Methamphetamine /Gastric Qualitative (HCPCS: G0480) 645 Methaqualone (Quaalude ) (HCPCS: G0480) Methaqualone Clinical Screen, with Confirmation, 7177 Methaqualone Screen with Confirmation, 6197 Methaqualone, GC/MS, (HCPCS: G0480) 6199 Methaqualone, Qualitative, GC/MS, (HCPCS: G0480) 479 Metharbital and Metabolite (HCPCS: G0480) Methsuximide as Metabolite (HCPCS: G0480) 8457 Methylenedioxymethamphetamine (MDMA) (HCPCS: G0480) 8304 Midazolam (HCPCS: G0480) Midazolam as Metabolite, (HCPCS: G0480) 3139 Midazolam, Blood (HCPCS: G0480) 6215 Morphine (HCPCS: G0480) Morphine (Free and Total), Serum/Plasma (HCPCS: G0480) Morphine, Quantitative, (HCPCS: G0480) Nalbuphine-Free (Unconjugated), Serum/Plasma (HCPCS: G0480) Naloxone, Quantitative, (HCPCS: G0480) Naltrexone and Metabolite Confirmation, Free (Unconjugated) (HCPCS: G0480) Nicotine and Cotinine, LC/MS/MS (HCPCS: G0480) Nicotine and Cotinine, LC/MS/MS, (HCPCS: G0480) Nicotine and Expanded Metabolites, LC/MS/MS (HCPCS: G0480)
27 DOS Name Nicotine and Expanded Metabolites, LC/MS/MS, (HCPCS: G0480) Nicotine and Metabolite, Fluid (HCPCS: G0480) Nicotine Metabolite Screen (HCPCS: G0479) Nicotine, Serum (HCPCS: G0480) 8333 Nitrazepam and Metabolites, Serum/Plasma (HCPCS: G0480) 272 Nortriptyline (HCPCS: G0480) Opiate Confirmation by GCMS, 80361, (HCPCS: G0480) Opiate Confirmation, GC/MS 80361, (HCPCS: G0480) Opiate Metabolites Screen with Confirmation 7179 Opiate Metabolites Screen with Confirmation, Opiates 2000, GC/MS, (HCPCS: G0480) Opiates 5, Qualitative, 80361, (HCPCS: G0480) Opiates 5, Quantitative, 80361, (HCPCS: G0480) Opiates Clinical Screen with Confirmation Opiates Clinical Screen, with Confirmation, Opiates Clinical Screen, without Confirmation, Opiates Confirmation, Enhanced Sensitivity, 80361, (HCPCS: G0480) Opiates Confirmation, GC/MS, Meconium 80361, (HCPCS: G0480) Opiates Confirmation, LC/MS/MS 80361, (HCPCS: G0480) Opiates Metabolites, GC/MS, 80361, (HCPCS: G0480) Opiates, Expanded (100), Qualitative, GC/MS, (HCPCS: G0480) Opiates, Expanded by GC/MS, 80361, (HCPCS: G0480)
28 DOS Name Opiates, Expanded, GC/MS, 80361, (HCPCS: G0480) Opiates, Progressive Opiates, Serum 80361, 80365, (HCPCS: G0480) 6232 Opiates, GC/MS, (HCPCS: G0480) Opiates, Qualitative, GC/MS, (HCPCS: G0480) Oxazepam (HCPCS: G0480) Oxycodone and Metabolite, GC/MS, (HCPCS: G0480) Oxycodone and Metabolite, Quantitative (HCPCS: G0480) Oxycodone and Metabolite, Quantitative, (HCPCS: G0480) Oxycodone and Metabolite, with Quantitative Confirmation, Oxycodone Confirmation, Qualitative (HCPCS: G0480) Oxycodone Confirmation, GC/MS, (HCPCS: G0480) Oxycodone Screen and Confirmation, Oxycodone, Qualitative without Confirmation, (REFL) Oxycodone, Qualitative, GC/MS, (HCPCS: G0480) 3111 Oxycodone, Qualitative, without Confirmation, Oxycodone, with Qualitative Confirmation, Oxycodone, with Quantitative Confirmation, Pain Management Base Profile with Confirmation,, 84311, 82570, Pain Management Base Profile with Confirmation, without medmatch,, 82570, 83986, Pain Management Base Profile without Confirmation,, 84311, 82570, Pain Management Profile 1 with Confirmation,, 82570, 83986, 84311
29 DOS Name Pain Management Profile 1 with Confirmation, with D/L Isomers, Pain Management Profile 1 with Confirmation, with D/L Isomers, w/o medmatch Pain Management Profile 1 with Confirmation, without medmatch,, 84311, 82570, 83986, 84311, 82570, 83986, 84311, 82570, Pain Management Profile 1 without Confirmation,, 84311, 82570, Pain Management Profile 2 with Confirmation,, 84311, 82570, Pain Management Profile 2 with Confirmation, without medmatch,, 84311, 82570, Pain Management Profile 2 without Confirmation,, 84311, 82570, Pain Management Profile 3 with Confirmation,, 84311, 82570, Pain Management Profile 3 with Confirmation, without medmatch,, 82570, 83986, Pain Management Profile 3 without Confirmation,, 84311, 82570, Pain Management Profile 4 with Confirmation,, 84311, 82570, Pain Management Profile 4 with Confirmation, without medmatch,, 84311, 82570, Pain Management Profile 4 without Confirmation,, 84311, 82570, Pain Management Profile 5 with Confirmation,, 82570, 83986, Pain Management Profile 5 with Confirmation, with D/L Isomers, Pain Management Profile 5 with Confirmation, without medmatch, Pain Management Profile 5 with Confirmation,with D/L Isomers, w/o medmatch, 84311, 82570, 83986, 82570, 83986, 84311, 84311, 82570, Pain Management Profile 5 without Confirmation, 80301, 82570, 83986, (HCPCS: G0479)
30 DOS Name Pain Management Profile 6 with Confirmation,, 84311, 82570, Pain Management Profile 6 with Confirmation, without medmatch,, 84311, 82570, Pain Management Profile 7 with Confirmation,, 84311, 82570, Pain Management Profile 7 with Confirmation, without medmatch,, 84311, 82570, Pain Management Profile 8 with Confirmation,, 84311, 82570, Pain Management Profile 8 with Confirmation, without medmatch,, 84311, 82570, Pain Management, Alcohol Metabolites, Quantitative, (HCPCS: G0480) Pain Management, Alcohol Metabolites, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Alcohol Metabolites, with Confirmation, (HCPCS: G0480) Pain Management, Alcohol Metabolites, with Confirmation, with medmatch, (HCPCS: G0480) Pain Management, Amphetamines, Quantitative, (HCPCS: G0480) Pain Management, Amphetamines, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Amphetamines, with Confirmation, Pain Management, Amphetamines, with Confirmation, with D/L Isomers, Pain Management, Amphetamines, with Confirmation, with D/L Isomers, with medmatch, Pain Management, Amphetamines, with Confirmation, with medmatch, Pain Management, Amphetamines, with D/L Isomers, Quantitative, (HCPCS: G0480)
31 DOS Name Pain Management, Amphetamines, with D/L Isomers,Quantitative,w/medMATCH, (HCPCS: G0480) Pain Management, Amphetamines, without Confirmation, Pain Management, Barbiturates, Quantitative, (HCPCS: G0480) Pain Management, Barbiturates, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Barbiturates, with Confirmation, Pain Management, Barbiturates, with Confirmation, with medmatch, Pain Management, Barbiturates, without Confirmation, Pain Management, Benzodiazepines, Quantitative, (HCPCS: G0480) Pain Management, Benzodiazepines, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Benzodiazepines, with Confirmation, Pain Management, Benzodiazepines, with Confirmation, with medmatch, Pain Management, Benzodiazepines, without Confirmation, Pain Management, Buprenorphine and Naloxone, Quantitative, 80348, (HCPCS: G0480) Pain Management, Buprenorphine, Quantitative, (HCPCS: G0480) Pain Management, Buprenorphine, Quantitative, with medmatch, Pain Management, Buprenorphine, with Confirmation including Naloxone (HCPCS: G0480) Pain Management, Buprenorphine, with Confirmation, Pain Management, Buprenorphine, with Confirmation, with medmatch,
32 DOS Name Pain Management, Buprenorphine, without Confirmation, Pain Management, Carisoprodol Metabolite, Quantitative, (HCPCS: G0480) Pain Management, Cocaine Metabolite, Quantitative, (HCPCS: G0480) Pain Management, Cocaine Metabolite, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Cocaine Metabolite, with Confirmation, Pain Management, Cocaine Metabolite, with Confirmation, with medmatch, Pain Management, Cocaine Metabolite, without Confirmation, Pain Management, Fentanyl, Quantitative, (HCPCS: G0480) Pain Management, Fentanyl, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Heroin Metabolite, Quantitative, (HCPCS: G0480) Pain Management, Heroin Metabolite, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Heroin Metabolite, with Confirmation, Pain Management, Heroin Metabolite, with Confirmation, with medmatch, 80301, 84311, 82570, (HCPCS: G0479) Pain Management, Heroin Metabolite, without Confirmation, Pain Management, Marijuana Metabolite, Quantitative, (HCPCS: G0480) Pain Management, Marijuana Metabolite, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Marijuana Metabolite, with Confirmation, Pain Management, Marijuana Metabolite, with Confirmation, with medmatch, Pain Management, Marijuana Metabolite, without Confirmation,
33 DOS Name Pain Management, MDMA, without Confirmation, Pain Management, MDMA/MDA, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, MDMA/MDA, Quantitative, (HCPCS: G0480) Pain Management, MDMA/MDA, with Confirmation, Pain Management, MDMA/MDA, with Confirmation, with medmatch, Pain Management, Meperidine, Quantitative, (HCPCS: G0480) Pain Management, Meperidine, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Methadone Metabolite, Quantitative, (HCPCS: G0480) Pain Management, Methadone Metabolite, with Confirmation, Pain Management, Methadone Metabolite, with Confirmation, with medmatch, Pain Management, Methadone Metabolite, without Confirmation, Pain Management, Methadone, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Methamphetamine D/L Isomers, (HCPCS: G0480) Pain Management, Methylphenidate Metabolite, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Methylphenidate Metabolite, Quantitative, (HCPCS: G0480) Pain Management, Opiates Expanded, Quantitative, 80361, (HCPCS: G0480) Pain Management, Opiates Expanded, Quantitative, with medmatch, 80361, (HCPCS: G0480) Pain Management, Opiates, with Confirmation, Pain Management, Opiates, with Confirmation, with medmatch,
34 DOS Name Pain Management, Opiates, without Confirmation, Pain Management, Oxycodone, Quantitative, (HCPCS: G0480) Pain Management, Oxycodone, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Oxycodone, with Confirmation, Pain Management, Oxycodone, with Confirmation, with medmatch, Pain Management, Oxycodone, without Confirmation, Pain Management, Phencyclidine, with Confirmation, Pain Management, Phencyclidine, with Confirmation, with medmatch, Pain Management, Phencyclidine, without Confirmation, Pain Management, Pregabalin, Quantitative, (HCPCS: G0480) Pain Management, Pregabalin, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Propoxyphene Metabolite, Quantitative, (HCPCS: G0480) Pain Management, Propoxyphene Metabolite, Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Propoxyphene, with Confirmation, Pain Management, Propoxyphene, with Confirmation, with medmatch, Pain Management, Propoxyphene, without Confirmation, Pain Management, Synthetic Stimulants Quantitative, with medmatch, (HCPCS: G0480) Pain Management, Synthetic Stimulants, Quantitative, (HCPCS: G0480) Pain Management, Tapentadol, Quantitative, (HCPCS: G0480) Pain Management, Tapentadol, Quantitative, with medmatch, (HCPCS: G0480)
35 DOS Name Pain Management, Tramadol, Quantitative, (HCPCS: G0480) Pain Management, Tricyclic Antidepressants, Quantitative, (HCPCS: G0480) Pain Management, Tricyclic Antidepressants, Quantitative, with medmatch, (HCPCS: G0480) 700 Pentobarbital (HCPCS: G0480) 8306 Percodan, Blood 80329, (HCPCS: G0480) Perphenazine, Serum/Plasma (HCPCS: G0480) Phencyclidine Clinical Screen with Confirmation, Phencyclidine Clinical Screen, with Confirmation, Phencyclidine Clinical Screen, without Confirmation, Phencyclidine Confirmation Qualitative, Meconium (HCPCS: G0480) 7180 Phencyclidine Screen with Confirmation Phencyclidine Screen, S/P Phencyclidine, Confirmation, GC/MS, Meconium (HCPCS: G0480) Phencyclidine, Qualitative, GC/MS, (HCPCS: G0480) 6261 Phenothiazines, Qualitative, (HCPCS: G0479) 6261 Phenothiazines, Qualitative, (HCPCS: G0479) 3474 Phentermine (HCPCS: G0480) Progressive Drug Screen # Promethazine, Serum/Plasma (HCPCS: G0480) Propoxyphene Clinical Screen with Confirmation Propoxyphene Clinical Screen, with Confirmation, Propoxyphene Clinical Screen, without Confirmation,
36 DOS Name 7181 Propoxyphene Screen with Confirmation 8419 Propoxyphene, GC/MS, (HCPCS: G0480) 6282 Propoxyphene, Qualitative, GC/MS, (HCPCS: G0480) Propoxyphene, Quantitative, GC/MS, Serum (HCPCS: G0480) 2339 Risperidone (HCPCS: G0480) 805 Salicylate (HCPCS: G0480) 817 Secobarbital (HCPCS: G0480) 3384 Selegiline and Metabolites (HCPCS: G0480) 8871 Sertraline and Desmethylsertraline, Serum/Plasma (HCPCS: G0480) Sports I Expanded (HCPCS: G0480) 1024 Strychnine Screen, Blood (HCPCS: G0479) 855 Strychnine Screen, Serum/Plasma (HCPCS: G0479) 8305 Strychnine Screen, (HCPCS: G0479) 7380 Substance Abuse Panel Substance Abuse Panel 10 with Confirmation, Substance Abuse Panel 10 with Opiates, 3023 Substance Abuse Panel with Confirmation, 6440 Substance Abuse Panel 10-20, GC/MS Confirmation Substance Abuse Panel Plus with Opiates 6633 Substance Abuse Panel with Confirmation, Substance Abuse Panel with Creatinine Substance Abuse Panel with Opiates,
37 DOS Name 6402 Substance Abuse Panel 10-50, with Confirmation 7182 Substance Abuse Panel 2-50, GC/MS 7908 Substance Abuse Panel Substance Abuse Panel Substance Abuse Panel 5-50 GC/MS 6405 Substance Abuse Panel 5-50 GC/MS 7505 Substance Abuse Panel Substance Abuse Panel Substance Abuse Panel plus Ethanol with Confirmation, 6636 Substance Abuse Panel 6-50 GC/MS 6403 Substance Abuse Panel 6-50 with Confirmation Substance Abuse Panel 6-50 with Opiates, 6630 Substance Abuse Panel 7 GC/MS Substance Abuse Panel 7 plus Heroin and LSD with Confirmation, 80361, 80323, 80349, 83992, 80326, 80345, 80346, 80361, (HCPCS: G0481) 1094 Substance Abuse Panel 7, with Confirmation, 5796 Substance Abuse Panel 7-50 GC/MS Substance Abuse Panel 7-50 plus Ethanol, with Confirmation, Substance Abuse Panel 7-50, Confirmed 6406 Substance Abuse Panel 7-50, GC/MS, Substance Abuse Panel 8-50 Plus Ethanol with Confirmation, 7641 Substance Abuse Panel 8-50 with Confirmation
38 DOS Name Substance Abuse Panel 8-50 plus Ethanol with Confirmation, 1262 Substance Abuse Panel 8-50, with Confirmation, 6581 Substance Abuse Panel Substance Abuse Panel Substance Abuse Panel 9 with Confirmation, Special, Substance Abuse Panel 9-50 Plus Ethanol with Confirmation, Synthetic Cannabinoid Metabolites Screen, Expanded, (HCPCS: G0480) Synthetic Cannabinoid Metabolites Screen, (HCPCS: G0479) Synthetic Cannabinoid Panel 1, (HCPCS: G0480) Synthetic Cannabinoid Panel 2, (HCPCS: G0480) Synthetic Cannabinoids, Qualitative, Serum (HCPCS: G0480) Synthetic Cannabinoids, Qualitative, (HCPCS: G0480) Synthetic Stimulants, Qualitative, Blood (HCPCS: G0480) Synthetic Stimulants, Qualitative, Serum (HCPCS: G0480) Synthetic Stimulants, Qualitative, (HCPCS: G0480) Synthetic Stimulants, Quantitative, (HCPCS: G0480) Tapentadol, Quantitative, (HCPCS: G0480) Temazepam (HCPCS: G0480) 6313 Temazepam and Oxazepam (HCPCS: G0480) THC Confirmation, GC/MS with Ratio 80349, (HCPCS: G0480) 4416 Thiopental and Metabolite (HCPCS: G0480) Thioridazine and Metabolite (HCPCS: G0480)
Tests Impacted by 2015 CPT Changes
Toxicology Changes for 2015 HPV Examples of Toxicology Panels Molecular Pathology, FISH and Anatomic Pathology 1 Toxicology Changes for 2015 80100 Test Code Dos Test Name 2015 2015 Medicare 5229 Drug Screen,
More informationJune 2016 Updated Crosswalk:
June 2016 Updated Crosswalk: 2016 HCPCS G0279 G6001 G6002 G6003 G6004 deleted f Radiology Coding BCBSNC currently considers this service investigational and will not cover either the HCPCS CPT s. Diagnostic
More informationThe CPT code for Human papillomavirus (HPV) has changed from 87621 to 87624. This code (87624) covers testing for HPV High Risk genotypes.
January 2015 2015 CPT Code Updates Dear Client: The American Medical Association (AMA) publishes the Current Procedural Terminology (CPT) Coding Manual on an annual basis. For 2015, the AMA made several
More informationClinical Drug Screening and/or Drug Testing
Manual: Policy Title: Reimbursement Policy Clinical Drug Screening and/or Drug Testing Section: Laboratory & Pathology Subsection: None Date of Origin: 10/26/2011 Policy Number: RPM016 Last Updated: 1/8/2016
More informationAn Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse
Drug Testing An Overview of Mayo Clinic Tests Designed for Detecting Drug Abuse Printed on August 18, 2016 1:59 pm CST 2016 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved.
More informationDUI in Southern Ohio MATT 2006
DUI in Southern Ohio MATT 2006 Laureen J. Marinetti, M.S., Ph.D. Chief Toxicologist Montgomery County Coroner s s Office & Miami Valley Regional Crime Lab (MVRCL) Dayton, Ohio Region The MVRCL is a regional
More informationPtProtect Pain Medication Management Program Monitors Patient Compliance
PHYSICIAN UPDATE 2013 Edition PtProtect Pain Medication Management Program Monitors Patient Compliance The PtProtect (Patient Protect) program offers pain medication management panels designed to improve
More informationPain Medication Management Program Monitors Patient Compliance
PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your
More informationConfirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment
Clinical Position Statement Confirmatory Drug Testing for Substance Abuse and Chronic Pain Treatment CLINICAL POSITION STATEMENT In most cases, immunoassay (qualitative) drug testing is sufficient for
More informationLC-MS for Pain Management Support. Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories
LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline Overview of drug testing, as a component of the therapeutic plan, in the management of chronic
More informationLC-MS for Pain Management Support
LC-MS for Pain Management Support Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories Outline Overview of drug testing, as a component of the therapeutic plan, in the management of chronic
More informationPAYMENT POLICY STATEMENT
PAYMENT POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 01/01/2014 04/05/2017 04/05/2016 Policy Name Policy Number Drug Screening Tests PY-0020 Policy Type
More informationComprehensive LC/MS Analysis of Illicit and Pain Management Drugs, Including Their Metabolites, in Urine
Comprehensive LC/MS Analysis of Illicit and Pain Management Drugs, Including Their Metabolites, in Urine Application Note Authors Peter JW Stone and Kevin McCann Agilent Technologies, Inc. Santa Clara,
More information2015 CPT Code Changes ACL Test
Changes ACL Test Test Description UCOMP DRUG SCREEN COMPLETE 80100 80303 G0431 UDINV DRUG INVESTIGATION 80100 80303 G0431 UTLC THIN LAYER CHROMATOGRAPHY DRUG SCREEN 80100 80303 G0431 UNIC NICOTINE, URINE
More informationUrine Drug Toxicology and Pain Management Testing. Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA
Urine Drug Toxicology and Pain Management Testing Kara Lynch, PhD, DABCC University of California San Francisco San Francisco, CA Learning Objectives Describe what chronic pain is, who is affected and
More informationUrine drug screens. Screening Methods
Screening Methods Urine drug screens Urine drug screens are generally performed using either immunoassays or gas chromatography-mass spectrometry (GC-MS). 2 Immunoassay UDS contain specific antibodies
More informationCITY OF MONTEREY Substance Abuse Policy General Employees of Monterey (GEM) July 1, 2003
Page 1 ATTACHMENT C CITY OF MONTEREY Substance Abuse Policy General Employees of Monterey (GEM) July 1, 2003 PURPOSE This policy provides guidelines for the detection and deterrence of alcohol and drug
More informationCollection Instructions for ARUP Drug Screen Kit #49204
Collection Instructions for ARUP Drug Screen Kit #49204 Manufacturer Purpose of Kit / Reagent (tests) Kit / Reagent Contents (list components) Other Supplies Needed ARUP Laboratories For Point of Collection
More informationInteragency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)
Appendix D: Urine Drug Testing for Monitoring Opioid Therapy i. Monitoring opioid therapy with urine drug testing (UDT) ii. UDT algorithm for monitoring opioid therapy iii. UDT clinical vignettes iv. Frequently
More informationDrug Utilization Is On The Rise
Objectives Identify the clinical issues related to opioid prescribing for chronic pain indications Define the clinical needs and expectations of urine drug testing in pain management Address preanalytical
More informationSection: Laboratory Last Reviewed Date: December 2015. Policy No: 68 Effective Date: April 1, 2016
Medical Policy Manual Topic: Urine Drug Testing for Substance Abuse and Chronic Pain Date of Origin: December 2015 Section: Laboratory Last Reviewed Date: December 2015 Policy No: 68 Effective Date: April
More informationThe potential of oral fluid as a specimen in various drug testing programs
The potential of oral fluid as a specimen in various drug testing programs *Christine Moore, Cynthia Coulter, Katherine Crompton, Warren Rodrigues, Michael Vincent, James Soares Immunalysis Corporation,
More informationDrug Testing in the Pain Management Setting
Drug Testing in the Pain Management Setting September 27, 2011 Gwen McMillin, PhD, DABCC University of Utah, ARUP Laboratories Disclosure Laboratory director consultant for Clinical Lab Consulting, LLC
More informationWhat Does the Drug Test Tell Us
What Does the Drug Test Tell Us QUALITATIVE TOXICOLOGY TESTING for CLINICAL MANAGEMENT of the PATIENT Background The qualitative drug test is often referred to as the drug screen - a misnomer Testing performed
More informationOU MEDICAL CENTER Human Resource Policy and Procedure Manual. Subject: Drug and Alcohol
OU MEDICAL CENTER Human Resource Policy and Procedure Manual Subject: Drug and Alcohol Section: HR 6-10 Page: 1 of 5 Origination Date: 6/2004 Revision Date: 2/2006, 9/2008, 7/2009 Coverage: All OUMC employees
More informationName of Policy: Urine Drug Testing in Pain Management
Name of Policy: Urine Drug Testing in Pain Management Policy #: 566 Latest Review Date: February 2015 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule, benefits are payable
More informationSimultaneous Quantitation of 43 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method
Simultaneous Quantitation of 4 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method Xiang He and Marta Kozak, Thermo Fisher Scientific, San Jose, CA Application Note 76 Key Words TSQ Quantum Access
More informationSMART DISCHARGE. Client s Name: Client ID: Partial Hospitalization Clinically Managed Medium Intensity Residential Treatment
SMART DISCHARGE Client s Name: Client ID: DATE OF DISCHARGE: Reason for Discharge Completed Treatment no further treatment needed Completed Treatment Plan/Referred Incomplete Client Left Before Completing
More information2013 IDAHO STATE POLICE FORENSIC SERVICES: TOXICOLOGY TRENDS
Toxicology Program Trends 213 213 IDAHO STATE POLICE FORENSIC SERVICES: TOXICOLOGY TRENDS Overview and Background This report discusses trends in the toxicology program, as well as the number of toxicology
More informationWhat Americans Believe. Grant Beardsley, MS, MT(ASCP) 10/12/2015. Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse
Interpreting: Urine Drug Test Results in Chronic Opioid Therapy and Drugs of Abuse Grant D. Beardsley, M.S., MT(ASCP) Clinical Toxicologist, Grant Beardsley, MS, MT(ASCP) I have nothing to disclose. I
More informationUnderstanding Drug Screens & PharmCAS Drug Screening Program Overview. Suzi Arant, Senior Business Developer July 8, 2011
Understanding Drug Screens & PharmCAS Drug Screening Program Overview Suzi Arant, Senior Business Developer July 8, 2011 Presentation Overview Drug Screening in Healthcare Drug Screening Panels Drugs of
More informationJuly 1, 2015 VIA EMAIL
July 1, 2015 VIA EMAIL Marc Hartstein Director, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Mail Stop C4-01-26 Baltimore, MD 21244 Dear Marc:
More informationClinic Reference Guide
Clinic Reference Guide 2010 Alliance Toxicology LLC PO Box 5000, PMB 190 Rancho Santa Fe, CA 92067 AllianceToxicologyLLCprovidesclinicaldrugtestingservicesforphysicians.Our companyprovidesacomprehensivedrugtestingpanelwhichincludesover40
More informationUrine Drug Testing Methadone 101 Methadone for hospitalists
Urine Drug Testing Methadone 101 Methadone for hospitalists Dr. Patricia Mark MB, BCh LEARNING OBJECTIVES Clarify the purpose of urine drug testing Distinguish between UDT for detection of illicit drug
More informationToxicology/DAU Testing by Mass Spectrometry
Toxicology/DAU Testing by Mass Spectrometry AACC Conference: Mass Spectrometry in the Clinical Lab September 17, 2013 Kara Lynch, PhD, DABCC University of California San Francisco Disclosures Research
More information2013 Annual Toxicology Report
213 Annual Toxicology Report Department of Justice Forensic Science Division Toxicology Department 2679 Palmer Street Missoula, MT 5988 DOJTOX@mt.gov Personnel Phil Kinsey Scott Larson Scott Schlueter
More informationSimultaneous Quantitation of 78 Drugs and Metabolites in Urine with a Dilute-And-Shoot LC MS-MS Assay
Journal of Analytical Toxicology 2015;1 12 doi:10.1093/jat/bkv024 Journal of Analytical Toxicology Advance Access published April 1, 2015 Article Simultaneous Quantitation of 78 Drugs and Metabolites in
More informationIndiana State Department of Toxicology 2012 Annual Report
Indiana State Department of Toxicology 2012 Annual Report Pictured on the cover is the State of Indiana Forensic and Health Sciences Laboratories facility housing the Indiana State Department of Toxicology.
More informationClinical Drug Testing in Primary Care
Clinical Drug Testing in Primary Care Technical Assistance Publication Series TAP 32 Clinical Drug Testing in Primary Care TAP Technical Assistance Publication Series 32 U.S. DEPARTMENT OF HEALTH AND
More informationAppropriate Use of UDT to Improve Patient Care
Published on OpioidRisk (http://www.opioidrisk.com) Home > Urine Drug Testing Urine Drug Testing This guide provides: Download Entire Guide [1] Appropriate use of Urine Drug Testing (UDT) to improve patient
More informationOral Fluid Drug Testing March 23 rd, 2015
Oral Fluid Drug Testing March 23 rd, 2015 Drug Testing Options Breath Blood Meconium Vitreous Hair Sweat Urine Oral Drug Testing Options Oral Fluid and Blood and Breath Actual levels (immediate use, up
More informationMaking the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications
TECHNICAL NOTE Toxicology Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications Introduction The resolving power of chromatography combined with
More informationOral Fluid as an alternative matrix in workplace drug testing: which drugs at which cutoff concentration?
Oral Fluid as an alternative matrix in workplace drug testing: which drugs at which cutoff concentration? Michael Böttcher MVZ Labor Dessau Gmb, Dessau, Germany a d d i c t i o n / a b u s e r e l e v
More informationUpdate on Drug Impaired Driving. WTSC Impaired Driver Conference SeaTac, December 2006
Update on Drug Impaired Driving WTSC Impaired Driver Conference SeaTac, December 2006 12/4/2007 Alcohol, Drugs and Driving Household Survey, 2004 (prior year) Any Illicit Drug Use 19.9 Million 8.3% Marijuana
More information1. Carrying Personal Medications into Thailand A. Medications containing narcotic drugs of category 2
Guidance for Travellers to Thailand under Treatment Carrying Personal Medications Containing Narcotic Drugs/Psychotropic Substances into/out of Thailand This guidance issued by the Narcotics Control Division,
More informationThis is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics
This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion
More informationMaking the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications
Making the Leap to LC/MS/MS: Enhancing and Accelerating Clinical Research and Forensic Toxicology Applications Introduction The resolving power of chromatography combined with the sensitivity and selectivity
More informationAppropriate utilization of drug tests for pain management patients
Appropriate utilization of drug tests for pain management patients Gwen McMillin, PhD, DABCC (CC, TC) Medical Director, Toxicology, ARUP Laboratories Associate Professor (clinical), University of Utah
More informationUrine Drug Testing of Chronic Pain Patients: Licit and Illicit Drug Patterns
Urine Drug Testing of Chronic Pain Patients: Licit and Illicit Drug Patterns Edward J. Cone* Johns Hopkins School of Medicine, Baltimore, Maryland Yale H. Caplan National Scientific Services, Baltimore,
More informationImplementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center
Clinical Chemistry / POC Testing f o r Dr u g s o f Ab u s e in t h e ED Implementation of Point-of-Care Rapid Urine Testing for Drugs of Abuse in the Emergency Department of an Academic Medical Center
More informationHillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction
Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction Drug testing beyond the health care and criminal justice systems has
More informationChanges to CPT Coding for 2015
Changes to CPT Coding for 2015 The American Medical Association (AMA) publishes the Current Procedural Terminology (CPT) coding manual on an annual basis. For 2015, the pathology and laboratory section
More informationDrug Usage in Pilots Involved in Aviation Accidents Compared With Drug Usage in the General Population: From 1990 to 2005
DOT/FAA/AM-08/10 Office of Aerospace Medicine Washington, DC 20591 Drug Usage in Pilots Involved in Aviation Accidents Compared With Drug Usage in the General Population: From 1990 to 2005 Sabra R. Botch
More informationDiagnostic Accuracy and Interpretation of Urine Drug Testing for Pain Patients: An Evidence-Based Approach
Diagnostic Accuracy and Interpretation of Urine Drug Testing for Pain Patients: An Evidence-Based Approach Amadeo Pesce 1, Cameron West 1, Kathy Egan-City 1 and William Clarke 2 2 1 Millennium Research
More informationWhy do employers drug test? How is drug testing conducted and how accurate is it?
Workplace Drug Testing Drug testing is one action an employer can take to determine if employees or job applicants are using drugs. It can identify evidence of recent use of alcohol, prescription drugs
More informationDRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015
DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015 The signatory parties recognize that drug abuse is an illness that creates serious problems for workers, their families, the workplace and
More informationFLORIDA DEPARTMENT OF LAW ENFORCEMENT SEPTEMBER 2013. 2012 Report
FLORIDA DEPARTMENT OF LAW ENFORCEMENT SEPTEMBER 2013 2012 Report Data Collection The Office of Vital Statistics reported more than 178,000 deaths occurred in Florida during 2012. Of these, the medical
More information15.110 ALCOHOL AND DRUG TESTING OF DEPARTMENT PERSONNEL
15.110 ALCOHOL AND DRUG TESTING OF DEPARTMENT PERSONNEL Reference: Administrative Regulation #52 (06/07) Manual of Rules and Regulations: 1.01, 1.02, 2.26 A/B, 6.01, 6.02 A/B, 6.03, 6.04, 6.05, 11.03 Public
More informationImproved Method for the Analysis of 31 Drugs of Abuse in Oral Fluid samples using the Thomson extreme FV by LC-MS/MS
htslabs.com folks@htslabs.com 800 541.4792 760 757.8080 760 757.9367 Improved Method for the Analysis of 31 Drugs of Abuse in Oral Fluid samples using the Thomson extreme FV by LC-MS/MS Nadine Koenig 2,
More informationContractor Information
Local Coverage Determination (LCD): Controlled Substance Monitoring and Drugs of Abuse Testing (L35006) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
More informationA Generic LC-MS Method for the Analysis of Multiple of Drug of Abuse Classes with the Thermo Scientific Exactive TM System
A Generic LC-MS Method for the Analysis of Multiple of Drug of Abuse Classes with the Thermo Scientific Exactive TM System Kent Johnson Fortes lab, Wilsonville Oregon List of drug of abuse candidates for
More informationHELPING YOUR BUSINESS DO MORE Webinar Series
HELPING YOUR BUSINESS DO MORE Webinar Series The Employers Council of Iowa, the Greater Des Moines Partnership, Kaplan University and Iowa Works bring you a series of educational webinars. These webinars
More informationFREQUENTLY ASKED QUESTIONS Oral Fluid Drug Testing with Oral-Eze
FREQUENTLY ASKED QUESTIONS Oral Fluid Drug Testing with Oral-Eze BENEFITS AND PRICING Q: What benefits does Oral-Eze present? A: The Oral-Eze Oral Fluid Collector has a built-in indicator for determining
More informationThe DRE DUI & DRUGS. Captain George Crum Fullerton Police Department
The DRE DUI & DRUGS Captain George Crum Fullerton Police Department What is a DRE? Drug Recognition Expert Experienced officer Selected by their department Special training in detecting drug influence/impairment
More informationThe Effects Of Drug Abuse On Dialysis
DRUGS OF ABUSE IN THE DIALYSIS POPULATION 2 0 1 4 H E A R T L A N D K I D N E Y C O N F E R E N C E Jamie Killion, PharmD, BCPS MEDICAL I N FORMATION SPECIALIST OBJECTIVES: Describe the magnitude of drug
More informationa. positive vs. negative reinforcement b. tolerance vs. sensitization c. drug classes einforcement
Drug Abuse (chapter 18) 1. Definitions iti a. positive vs. negative reinforcement b. tolerance vs. sensitization c. drug classes 2. Neural Mechanisms of Re einforcement a. mesolimbic dopamine system b.
More informationUtility of Oral Fluid in Compliance Monitoring of Opioid Medications
Pain Physician 2014; 17:63-70 ISSN 1533-3159 Prospective Evaluation Utility of Oral Fluid in Compliance Monitoring of Opioid Medications Till Conermann, MD, Ankur R. Gosalia, MD, Abraham Jack Kabazie,
More informationDiagnostic Accuracy Study Protocol. Pain Physician 2010; 13:E1-E22 ISSN 2150-1149. www.painphysicianjournal.com
Pain Physician 2010; 13:E1-E22 ISSN 2150-1149 Diagnostic Accuracy Study Protocol Protocol for Accuracy of Point of Care (POC) or In-Office Urine Drug Testing (Immunoassay) in Chronic Pain Patients: A Prospective
More informationPractical Aspects of Drug Testing in Human Hair
Practical Aspects of Drug Testing in Human Hair Laboratory Perspective James A. Bourland, Ph.D., DABFT FOR INTERNAL USE ONLY. NOT FOR PRINT OR DISTRIBUTION Overview of Collection Process FOR INTERNAL USE
More informationCentral Government Laboratory Department of Health and Environment
Central Government Laboratory Department of Health and Environment Overview who we are and what we do What is available and what is protocol for good science Sample collection Screening Tests Confirmation
More informationAppNote 6/2011. Determination of Pain Management Drugs using Automated Disposable Pipette Extraction and LC-MS/MS KEYWORDS ABSTRACT
AppNote 6/2011 Determination of Pain Management Drugs using Automated Disposable Pipette Extraction and LC-MS/MS Fred D. Foster, John R. Stuff, Edward A. Pfannkoch Gerstel, Inc., 701 Digital Dr. Suite
More informationSCID-I (for DSM-IV-TR) Alcohol Abuse (JAN 2010) Substance Use Disorders E. 2
SCID-I (for DSM-IV-TR) Alcohol Abuse (JAN 2010) Substance Use Disorders E. 2 *LIFETIME ALCOHOL ABUSE* IF DEFINITE PERIOD: Let me ask you a few more questions about (TIME WHEN DRINKING THE MOST OR HAD PROBLEMS).
More informationTriage TOX Drug Screen Product Insert Rapid Qualitative simultaneous detection of drug and/or the major urinary metabolites of 10 different drug
Triage TOX Drug Screen Product Insert Rapid Qualitative simultaneous detection of drug and/or the major urinary metabolites of 10 different drug classes (11 unique assays). Product Insert Catalog#: 94400
More informationHow To Understand The Health Effects Of Prescription Drugs
Miami-Dade, Broward and Palm Beach Counties, Florida Trends of Nonmedical Prescription Drug Misuse in Miami-Dade, Broward, Palm Beach Counties, and the State of Florida: 2010 James N. Hall 1 ABSTRACT The
More informationPrevalence and risk of driving under influence of psychoactive substances: Results from epidemiological studies
Downloaded from orbit.dtu.dk on: Nov 25, 2015 Prevalence and risk of driving under influence of psychoactive substances: Results from epidemiological studies Bernhoft, Inger Marie; Hels, Tove Publication
More informationDriving under the influence of non-alcohol drugs. legal limits implemented in Norway
Driving under the influence of non-alcohol drugs legal limits implemented in Norway Drug/drink driving a large killer on our roads Norway has a long-standing tradition of road safety, with low death rates
More informationHair Drug & Alcohol Testing FAQs
HAIR DRUG TESTING More than DNA Hair Drug & Alcohol Testing FAQs Need advice about testing? Contact us using our online SMS service or call Cellmark free on 0800 043 4247 2045 Introduction Cellmark is
More informationNeurotransmitters Made Easy: The Mood Teeter-Totter
Neurotransmitters Made Easy: The Mood Brad Lander PhD, LICDC Clinical Director / Psychologist Talbot Hall - Addiction Medicine at The Ohio State University Wexner Medical Center Key Point #1 Thinking and
More informationUrine Drug Testing. Why drug test? Set the Standard!
Urine Drug Testing Urine drug testing is a valuable tool for the physician when making treatment decisions. Patients and physicians benefit from safe and effective treatment of pain but there are always
More informationTHE DRUG AND ALCOHOL SCREENING PROGRAM
THE DRUG AND ALCOHOL SCREENING PROGRAM Revision 8- June 1 2014 Table of Contents Page Section 1 Introduction 3 Section 2 Commitment to Confidentiality 3 Section 3 Card Identification System 4 Section 4
More informationCUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES
CUT-OFF CONCENTRATIONS FOR DRUGS OF ABUSE IN SALIVA FOR DUI, DWI OR OTHER DRIVING-RELATED CRIMES Vina SPIEHLER 1, Dene BALDWIN 2, Christopher HAND 2 1 DABFT, Newport Beach, United States of America 2 Cozart
More informationDrug- and Alcohol-Related Intoxication Deaths in Maryland, 2014
Maryland Department of Health and Mental Hygiene Larry Hogan, Governor Boyd Rutherford, Lt. Governor Van Mitchell, Secretary May, 215 Drug- and Alcohol-Related Intoxication Deaths in Maryland, 214 Table
More informationDrugs of abuse testing (DAT) Detection of drug abuse and misuse using biological samples
Drugs of abuse testing (DAT) Detection of drug abuse and misuse using biological samples cobas modular platform Flexible configurations for tailor made solutions Introduction to DAT With the cobas modular
More informationMOSAIC DES MOINES Alcohol/Drug Free Workplace Policy
MOSAIC DES MOINES Alcohol/Drug Free Workplace Policy Purpose: To help safeguard employee health, provide a safe and productive workplace, and supply our people served with high quality service, Mosaic
More informationA Report on Marijuana and Prescription Drugs
Prescription Drug Misuse in America A Report on Marijuana and Prescription Drugs Table of Contents Summary 2 Prescription Drug Misuse is Prevalent 6 Marijuana: The Most Misused Drug 8 Recreational Marijuana
More informationREACH AIR MEDICAL SERVICES SUBSTANCE ABUSE POLICY FOR APPLICANTS APPLYING FOR SAFETY-SENSITIVE POSITIONS
EFFECTIVE DATE: 06/01/2013 REACH AIR MEDICAL SERVICES SUBSTANCE ABUSE POLICY FOR APPLICANTS APPLYING FOR SAFETY-SENSITIVE POSITIONS (FOR TESTING TO BE CONDUCTED IN CALIFORNIA [excluding the City of San
More informationRapid Screening Method for Illicit Drugs, Using an Advanced Solid Core UHPLC Column and UHPLC System with MS/MS Detection
Rapid Screening Method for Illicit Drugs, Using an Advanced Solid Core UHPLC Column and UHPLC System with MS/MS Detection Derek Hillbeck, Thermo Fisher Scientific, Runcorn, UK Application Note 2999 Key
More informationMonitoring Program (DMP) heroin purchase data (edited versions) were also utilized. Data were also obtained from the Threat Assessment Report
Drug Abuse Trends in the Seattle/King County Area: 2011 Caleb Banta-Green 1, T. Ron Jackson 2, Steve Freng 3, Michael Hanrahan 4, Geoff Miller 8, Steve Reid 5, John Ohta 6, Mary Taylor 7, Richard Harruff
More informationpunishment increased 1 degree. If force used, degree felony (3)(A) other opium and opiates Delivery of Penalty 1 Substance 180days-2yrs; <$10,000
PENALTY GROUP OFFENSES/PENALTIES ENHANCEMENTS/BENEFIT RESTRICTIONS 481.102 Penalty Group 1 (1) Opiates (2) Opium derivatives: e.g., codeine compounds, morphine compounds, heroin 481.112 Manufacture or
More informationDrug Abuse Patterns and Trends in the San Francisco Bay Area Update: June 2014
Drug Abuse Patterns and Trends in the San Francisco Bay Area Update: June 24 Alice A. Gleghorn, Ph.D. ABSTRACT In San Francisco, increases in heroin consequence indicators (treatment admissions and Drug
More informationHealth Safety Environmental Program SUBSTANCE ABUSE PREVENTION
Effective Date 06/01/2011 PROGRAM The policies and procedures of this substance abuse prevention program apply to all company operations. This program facilitates compliance with the Arkansas Drug Free
More informationImpairment based legislative limits for driving under the influence of non-alcohol drugs: The Norwegian experience
Impairment based legislative limits for driving under the influence of non-alcohol drugs: The Norwegian Vigdis Vindenes 1), Lars Slørdal 2) and Jørg Mørland 1) 1) Division of Forensic Medicine and Drug
More informationDrug Testing Reference Tables for Drug Courts
Drug Testing Reference Tables for Drug Courts July, 2009 Page 1 TABLE I. Specimen Detection Period Advantages Disadvantages URINE SWEAT (patch) ORAL FLUID (saliva) Provides a profile of both current and
More informationSubstance Abuse Prevention Program
Planning, Design and Construction 14528 S Outer Forty Suite 100 Chesterfield, MO 63017 (314) 628-3494 (314) 628-3715 Substance Abuse Prevention Program REFERENCES: In an effort to create a safe workplace,
More informationSubstance Abuse Prevention and Treatment Agency 2012 Community Profile
Substance Abuse Prevention and Treatment Agency 2012 Community Profile Nevada Division of Mental Health and Developmental Services Department of Health and Human Services Brian Sandoval, Governor Michael
More informationRationale for Urine Drug Testing (UDT)
Rationale for Urine Drug Testing (UDT) Help to identify drug misuse/addiction Prior to starting opioid treatment Assist in assessing adherence during opioid therapy As requirement of therapy w/ an opioid
More informationTRENDS IN ALCOHOL AND DRUG RELATED AMBULANCE ATTENDANCES IN MELBOURNE 2009 10
AMBO PROJECT: ALCOHOL AND DRUG RELATED AMBULANCE ATTENDANCES TRENDS IN ALCOHOL AND DRUG RELATED AMBULANCE ATTENDANCES IN MELBOURNE 2009 10 Belinda Lloyd ambo project: Alcohol and Drug Related Ambulance
More informationPatterns and Trends in Drug Abuse in Los Angeles County, California: 2013
Patterns and Trends in Drug Abuse in Los Angeles County, California: 2013 Mary-Lynn Brecht, Ph.D. 1 ABSTRACT A key finding in the Los Angeles area in this reporting period was the continuing increase in
More informationDrug Trends in Phoenix and Arizona: 2013
Drug Trends in Phoenix and Arizona: 213 James K. Cunningham, Ph.D. 1 ABSTRACT Two key findings for the Phoenix area (Maricopa County) in 213 were a 5-year increase in treatment admissions for other opioids
More information